Navigation Links
AcelRx Pharmaceuticals to Present at Two Near-Term Health Care Conferences
Date:2/21/2012

REDWOOD CITY, Calif., Feb. 21, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and Chief Executive Officer, will present at two separate investor conferences, one in New York City, NY and one in Boston, MA, over the coming weeks as follows:

Citi 2012 Global Health Care Conference
Date:  Tuesday, February 28th at 10:30 AM EST
Location:  Waldorf Astoria Hotel in New York, NY
Webcast link:  http://www.veracast.com/webcasts/citigroup/healthcare2012/07206633.cfm

Cowen and Company 32nd Annual Health Care Conference
Date:  Tuesday, March 6th at 9:20 AM EST
Location:  The Boston Marriott Copley Place in Boston, MA
Webcast link:  http://wsw.com/webcast/cowen6/acrx/

Both presentations will be webcast live and can be accessed through the links above.  For those not available to listen to the live broadcast, the presentations will be archived and available through http://www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
Based in Redwood City, CA, AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, which is in
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... 27, 2011 eResearchTechnology, Inc. (ERT), (Nasdaq: ... services and customizable medical devices to biopharmaceutical and ... safety and respiratory efficacy services in drug development, ... September 30, 2011.  Unless otherwise noted, all comparative ...
... VR Laboratories LLC today announced the appointment ... Officer. Kottkamp will oversee operations at VR Laboratories, ... world-class botanical consumer, medicinal food and beverage, and ... (Photo: http://photos.prnewswire.com/prnh/20111027/FL95170 ) ...
Cached Medicine Technology:ERT Reports Third Quarter 2011 Operating Results 2ERT Reports Third Quarter 2011 Operating Results 3ERT Reports Third Quarter 2011 Operating Results 4ERT Reports Third Quarter 2011 Operating Results 5ERT Reports Third Quarter 2011 Operating Results 6ERT Reports Third Quarter 2011 Operating Results 7ERT Reports Third Quarter 2011 Operating Results 8ERT Reports Third Quarter 2011 Operating Results 9ERT Reports Third Quarter 2011 Operating Results 10ERT Reports Third Quarter 2011 Operating Results 11ERT Reports Third Quarter 2011 Operating Results 12ERT Reports Third Quarter 2011 Operating Results 13Jeff Kottkamp Chosen to Lead VR Laboratories 2
(Date:7/25/2014)... The human brain can preserve oxygen to protect itself ... Although dehydration significantly reduces blood flow to ... brain compensates by increasing the amount of oxygen it ... us understand a lot more about how the human ... first author Steven Trangmar, a researcher at Brunel University, ...
(Date:7/25/2014)... July 25, 2014 A new study conducted ... revealed that 39 percent of all children in the survey under ... The survey looked at 2,505 children during the years of 2011 ... years of age. The final result was that about two ... Many of these children were from lower-income families and were of ...
(Date:7/25/2014)... July 25, 2014 On July ... Nuanced Media client and the nation’s number one ... employee handbooks, announced their partnership with TransAct Merchant ... a registered ISO/MSP of Chase Paymentech Solutions, LLC, ... processing industry. Companies that are members of TransAct’s ...
(Date:7/25/2014)... Philadelphia, PA (PRWEB) July 25, 2014 ... that Valerie D. Weber, MD, MS, FACP, has been appointed ... , Weber will join Drexel from The Commonwealth Medical College, ... Sciences, associate dean for clinical affairs, and professor of medicine. ... of The Commonwealth Medical College, Weber had a major role ...
(Date:7/25/2014)... 25, 2014 (HealthDay --, Treatment for lymphoma may lower ... and non-Hodgkin lymphoma, which are cancers of the body,s ... still in their reproductive years. For men, treatment for ... most men regain their fertility within two years of ... about the possibility of this significant side effect before ...
Breaking Medicine News(10 mins):Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2
... by blocking immune signaling by a protein receptor, a ... to protect against North American strains of the virus, ... the receptor’s key role in controlling West Nile infection ... Virology that compares the genetics of an illness-causing Texas ...
... been a sharp rise in the number of HIV cases in Victoria ... since the early 1990s//. ,In Victoria, nearly 200 new HIV ... an increase of 38% than at the same time last year. 129 ... ,The numbers have been on the rise since 1999, however, it rose ...
... the gray matter has offered an insight into a trait ... – SELFISHNESS//. Bewildering all the same, why are some people ... believe in being the epitome of selflessness! ,Scientists ... the front of the brain, termed as the dorsolateral prefrontal ...
... recent research, drinking cola can lead to brittle bones in ... carbonated drink women consumed, the weaker// were their bones. ... not to drink too much of cola. The phosphoric acid, ... is assumed to be responsible for the problem. ...
... Organization (WHO) for the first time issued Global Air Quality ... pollution that kills 2 million// people each year with most ... WHO appealed to governments to enhance air quality in the ... Manila revealed that almost 3,00,000 lives could be saved every ...
... reasons known to cause deaths in women in developing ... the number of deaths caused// because of uncontrolled bleeding ... extensive research and studies conducted by researchers from the ... the National Institutes of Health . The studies have ...
Cached Medicine News:Health News:Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development 2Health News:Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development 3Health News:Cola increases risk of Osteoporosis!! 2Health News:A Safe Drug For Safe Delivery 2
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
... Designed around the patented Interzeag ... 301 sets the trend in ... Ideal for routine screening and ... performance, accuracy and quality of ...
Focus Toric Monthly lenses. All the advantages of Focus Monthly lenses, now available for patients with astigmatism. Recommended for daily wear. Also approved for extended wear (1-7 days)....
Medicine Products: